1 Min Read
July 7 (Reuters) - ONCOLOGY VENTURE SWEDEN AB
* ONCOLOGY VENTURE AND EISAI FORGE EXCLUSIVE GLOBAL LICENSE AGREEMENT FOR CLINICAL STAGE ONCOLOGY DRUG PARP INHIBITOR E7449 / 2X-121 Source text for Eikon: Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.